177Lu-PSMA raDioligand therapy for prostate cancer

Journal of Nuclear Medicine

Volumn 58, Issue 8, 2017, Pages 1196-1200

  Fendler, Wolfgang P ^a,b   Rahbar, Kambiz ^c   Herrmann, Ken ^a,d   Kratochwil, Clemens ^e   Eiber, Matthias ^a,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Education; Genitourinary; Lutetium; PSMA; RaDionuclide therapy; Therapy

Indexed keywords

ANTIANDROGEN; GALLIUM 68; LUTETIUM 177; OXODOTREOTIDE LU 177; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; LUTETIUM; MEMBRANE ANTIGEN; RADIOISOTOPE;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; ANTIGEN EXPRESSION; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; CASTRATION RESISTANT PROSTATE CANCER; DOSIMETRY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FOLLOW UP; HUMAN; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; PATIENT CARE PLANNING; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SALIVARY GLAND DISEASE; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; MALE; METABOLISM; PROCEDURES; PROSTATIC NEOPLASMS; SAFETY;

ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LUTETIUM; MALE; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOTHERAPY; SAFETY;

EID: 85026520469     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.117.191023     Document Type: Article

References (47)

1. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65:124-137.
2. 177Lu-DOTATATE for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125-135.
3. 177Lu]lutetium-labelled PSMA ligandinduced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:987-988.
4. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-85.
5. Pyka T, Okamoto S, Dahlbender M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:2114-2121.
6. Ananias HJ, van den Heuvel MC, Helfrich W, de Jong IJ. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostatespecific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate. 2009;69:1101-1108.
7. 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85-90.
8. Baum RP, Kulkarni HR, Schuchardt C, et al. Lutetium-177 PSMA radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57:1006-1013.
9. Delker A, Fendler WP, Kratochwil C, et al. Dosimetry for Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:42-51.
10. Hohberg M, Eschner W, Schmidt M, et al. Lacrimal glands may represent organs at risk for radionuclide therapy of prostate cancer with [Lu]DKFZ-PSMA-617. Mol Imaging Biol. 2016;18:437-445.
11. 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:1976-1983.
12. Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. J Nucl Med. 2016;57:1170-1176.
13. Kulkarni HR, Singh A, Schuchardt C, et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka experience since 2013. J Nucl Med. 2016;57(suppl):97S-104S.
14. 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med. 2016;57:1334-1338.
15. 177Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer. J Urol. 2016;196: 382-391.
16. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging. 2017;44:81-91.
17. 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2017;8:3581-3590.
18. 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med. 2016;41:522-528.
19. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38:696-701.
20. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15:167-172.
21. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82:2256-2261.
22. Minner S, Wittmer C, Graefen M, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate. 2011;71:281-288.
23. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostatespecific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357-6362.
24. Schülke N, Varlamova OA, Donovan GP, et al. The homodimer of prostatespecific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci USA. 2003;100:12590-12595.
25. Rajasekaran SA, Anilkumar G, Oshima E, et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell. 2003;14:4835-4845.
26. Kozikowski AP, Nan F, Conti P, et al. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem. 2001;44:298-301.
27. Eder M, Schafer M, Bauder-Wust U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688-697.
28. 18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008;14:3036-3043.
29. Bene?sová M, Schafer M, Bauder-Wust U, et al. Preclinical evaluation of a tailormade DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914-920.
30. 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-ofconcept human studies. J Nucl Med. 2015;56:1169-1176.
31. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.
32. Pfob CH, Ziegler S, Graner FP, et al. Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CC: a PSMA specific probe for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:1962-1970.
33. 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer [in German]. Nuklearmedizin. 2016;55:123-128.
34. Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800-816.
35. Anthony LB,Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32:123-132.
36. 177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol Imaging. March 23, 2017 [Epub ahead of print].
37. Bohn KP, Kletting P, Solbach C, Beer AJ, Krohn T. Effekt der Kühlung von Speicheldrüsen bei der Therapie mit PSMA-Radioliganden. Nuklearmedizin. 2017;56:A2-A91.
38. Mottet N, Bellmunt J, Briers E, et al. Guidelines on Prostate Cancer. Arnhem, The Netherlands: European Association of Urology; 2015.
39. Murga JD, Moorji SM, Han AQ, Magargal WW, DiPippo VA, Olson WC. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate. 2015;75:242-254.
40. Hope TA, Truillet C, Ehman EC, et al. 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med. 2017;58:81-84.
41. 177Lu-PSMA-DKFZ-617 of castrateresistant metastatic prostate cancer. Oncotarget. 2016;7:12477-12488.
42. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-223.
43. 177Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. May 9, 2017 [Epub ahead of print].
44. Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402-1418.
45. Eiber M, Herrmann K. From NETTER to PETTER: PSMA-targeted radioligand therapy. J Nucl Med. 2017;58:9-10.
46. Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted alpha therapy of mCRPC with 225actinium-PSMA-617: dosimetry estimate and empirical dose finding. J Nucl Med. April 13, 2017 [Epub ahead of print].
47. Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMAtargeted alpha-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941-1944.